Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer

Approximately, 25–30% of early-stage breast tumors are classified at the molecular level as HER2-positive, which is an aggressive subtype of breast cancer. Amplification of the HER2 gene in these tumors results in a substantial increase in HER2 mRNA levels, and consequently, HER2 protein levels. HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Merry, Callie R., McMahon, Sarah, Forrest, Megan E., Bartels, Cynthia F., Saiakhova, Alina, Bartel, Courtney A., Scacheri, Peter C., Thompson, Cheryl L., Jackson, Mark W., Harris, Lyndsay N., Khalil, Ahmad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288181/
https://www.ncbi.nlm.nih.gov/pubmed/27449296
http://dx.doi.org/10.18632/oncotarget.10637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288181/
https://www.ncbi.nlm.nih.gov/pubmed/27449296
http://dx.doi.org/10.18632/oncotarget.10637

Ejemplares similares